LadRx Corporation

Equities

LADX

US2328287071

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:30:02 2024-05-16 am EDT			5-day change	1st Jan Change
3.2 ^USD	+3.23%		+15.94%	+146.15%

Mar. 27	LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 11	Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	DJ

CytRx Corporation Appoints Daniel Levitt as Chief Operating Officer

December 19, 2016 at 09:00 am EST

CytRx Corporation has appointed Daniel Levitt, M.D., Ph.D., the company's current Executive Vice President and Chief Medical Officer, to the newly created role of Chief Operating Officer. Going forward, Dr. Levitt will continue to serve as CytRx's Chief Medical Officer, a role he has held in since joining CytRx in 2009.

Latest news about LadRx Corporation

LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	Jan. 11	DJ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
LadRx Corporation has filed an IPO in the amount of $24 million.	23-04-14	CI
LadRx Highlights Patent Issued for Its LADR Technology	23-03-27	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
LadRx Corporation Auditor Raises 'Going Concern' Doubt	23-03-19	CI
LadRx Announces Review of Strategic Alternatives	23-03-15	CI
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
LadRx Corporation will Change its Ticker to LADX from CYTR	22-10-06	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
CytRx Corporation Appoints Cary J. Claiborne to its Board of Directors and as Member of Audit Committee and Chairperson of Compensation Committee	22-08-09	CI
CytRx Corporation Announces Director Changes	22-06-02	CI
CytRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
CytRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
CytRx Corporation Auditor Raises 'Going Concern' Doubt	22-03-22	CI
CytRx Corporation Announces Board Retirements	22-03-09	CI
Sector Update: Health Care Stocks Carried Back Near Even by Biotechs	22-02-24	MT
Cytrx Corporation Announces Changes to its Board	22-01-03	CI
CytRx Corporation Announces Executive Changes, Effective January 10, 2022	22-01-03	CI
CytRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
CytRx Corporation Highlights ImmunityBio, Inc.'s Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment	21-10-14	CI

Chart LadRx Corporation

Duration

Period

More charts

Company Profile

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Companyâs linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LADRX CORPORATION	+146.15%	1.53M
MODERNA, INC.	+33.13%	49.46B
IQVIA HOLDINGS INC.	+1.73%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.53%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.64B
BIO-TECHNE CORPORATION	+8.13%	13.16B
MEDPACE HOLDINGS, INC.	+29.18%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.33%	12.1B

Other Biotechnology & Medical Research